RIS-Aided Cell-Free Massive MIMO Systems for 6G: Fundamentals, System Design, and Applications

An introduction of intelligent interconnectivity for people and things has posed higher demands and more challenges for sixth-generation (6G) networks, such as high spectral efficiency and energy efficiency, ultra-low latency, and ultra-high reliability. Cell-free (CF) massive multiple-input multiple-output (mMIMO) and reconfigurable intelligent surface (RIS), also called intelligent reflecting surface (IRS), are two promising technologies for coping with these unprecedented demands. Given their distinct capabilities, integrating the two technologies to further enhance wireless network performances has received great research and development attention. In this paper, we provide a comprehensive survey of research on RIS-aided CF mMIMO wireless communication systems. We first introduce system models focusing on system architecture and application scenarios, channel models, and communication protocols. Subsequently, we summarize the relevant studies on system operation and resource allocation, providing in-depth analyses and discussions. Following this, we present practical challenges faced by RIS-aided CF mMIMO systems, particularly those introduced by RIS, such as hardware impairments and electromagnetic interference. We summarize corresponding analyses and solutions to further facilitate the implementation of RIS-aided CF mMIMO systems. Furthermore, we explore an interplay between RIS-aided CF mMIMO and other emerging 6G technologies, such as next-generation multiple-access (NGMA), simultaneous wireless information and power transfer (SWIPT), and millimeter wave (mmWave). Finally, we outline several research directions for future RIS-aided CF mMIMO systems.Comment: 30 pages, 15 figure

A Microgrid Energy Management Strategy Considering Carbon Quota Guided Demand Response

In order to reduce the forecast output error caused by the randomness and volatility of renewable energy in microgrid operation, a microgrid energy management strategy considering carbon quota guided demand response is proposed. A two-layer model predictive control (MPC) energy management model is constructed. The upper layer guides electric vehicles to participate in the demand response of microgrid by constructing a carbon emission quota mechanism to realize the economic operation of microgrid and reduce carbon emissions. The lower layer uses the model predictive control rolling optimization and the power fluctuation caused by the prediction error of renewable energy is suppressed by the short time scale model predictive control. The results of calculation analysis show that the proposed energy management strategy can effectively guide electric vehicles or other controllable loads to participate in demand response and realize low-carbon economic dispatch and stable operation of microgrid

Spatial variation of fouling behavior in high recovery nanofiltration for industrial reverse osmosis brine treatment towards zero liquid discharge

10.1016/j.memsci.2020.118185Journal of Membrane Science60911818

Two Compound Heterozygous Were Identified in Gene in Two Chinese Families With Enlarged Vestibular Aqueduct

Objectives To investigate the genetic causes of hearing loss with enlarged vestibular aqueduct (EVA) in two children from unrelated two Chinese families. Methods Sanger sequencing of all coding exons in SLC26A4 (encoding Pendrin protein) was performed on the two patients, their sibling and parents respectively. To predict and visualize the potential functional outcome of the novel variant, model building, structure analysis, and in silico analysis were further conducted. Results The results showed that the proband from family I harbored a compound heterozygote of SLC26A4 c.1174A>T (p.N392Y) mutation and c.1181delTCT (p.F394del) variant in exon 10, potentially altering Pendrin protein structure. In family II, the proband was identified in compound heterozygosity with a known mutation of c.919-2A>G in the splice site of intron 7 and a novel mutation of c.1023insC in exon 9, which results in a frameshift and translational termination, consequently leading to truncated Pendrin protein. Sequence homology analysis indicated that all the mutations localized at high conservation sites, which emphasized the significance of these mutations on Pendrin spatial organization and function. Conclusion In summary, this study revealed two compound heterozygous mutations (c.1174A>T/c.1181delTCT; c.919- 2A>G/c.1023insC) in Pendrin protein, which might account for the deafness of the two probands clinically diagnosed with EVA. Thus this study contributes to improve understanding of the causes of hearing loss associated with EVA and develop a more scientific screening strategy for deafness

A Bayesian reanalysis of the Standard versus Accelerated Initiation of Renal-Replacement Therapy in Acute Kidney Injury (STARRT-AKI) trial

Background Timing of initiation of kidney-replacement therapy (KRT) in critically ill patients remains controversial. The Standard versus Accelerated Initiation of Renal-Replacement Therapy in Acute Kidney Injury (STARRT-AKI) trial compared two strategies of KRT initiation (accelerated versus standard) in critically ill patients with acute kidney injury and found neutral results for 90-day all-cause mortality. Probabilistic exploration of the trial endpoints may enable greater understanding of the trial findings. We aimed to perform a reanalysis using a Bayesian framework. Methods We performed a secondary analysis of all 2927 patients randomized in multi-national STARRT-AKI trial, performed at 168 centers in 15 countries. The primary endpoint, 90-day all-cause mortality, was evaluated using hierarchical Bayesian logistic regression. A spectrum of priors includes optimistic, neutral, and pessimistic priors, along with priors informed from earlier clinical trials. Secondary endpoints (KRT-free days and hospital-free days) were assessed using zero–one inflated beta regression. Results The posterior probability of benefit comparing an accelerated versus a standard KRT initiation strategy for the primary endpoint suggested no important difference, regardless of the prior used (absolute difference of 0.13% [95% credible interval [CrI] − 3.30%; 3.40%], − 0.39% [95% CrI − 3.46%; 3.00%], and 0.64% [95% CrI − 2.53%; 3.88%] for neutral, optimistic, and pessimistic priors, respectively). There was a very low probability that the effect size was equal or larger than a consensus-defined minimal clinically important difference. Patients allocated to the accelerated strategy had a lower number of KRT-free days (median absolute difference of − 3.55 days [95% CrI − 6.38; − 0.48]), with a probability that the accelerated strategy was associated with more KRT-free days of 0.008. Hospital-free days were similar between strategies, with the accelerated strategy having a median absolute difference of 0.48 more hospital-free days (95% CrI − 1.87; 2.72) compared with the standard strategy and the probability that the accelerated strategy had more hospital-free days was 0.66. Conclusions In a Bayesian reanalysis of the STARRT-AKI trial, we found very low probability that an accelerated strategy has clinically important benefits compared with the standard strategy. Patients receiving the accelerated strategy probably have fewer days alive and KRT-free. These findings do not support the adoption of an accelerated strategy of KRT initiation